New results from its intepirdine (RVT-101) and nelotanserin research programs on Alzheimer’s disease (AD) and Lewy body dementia will be shared soon, Axovant Sciences announced. The data will be presented at the 2017 Alzheimer’s Association International Conference (AAIC) in London  July 16-20. Intepirdine is a selective antagonist of the…
People at risk for Alzheimer’s disease who spend more time doing moderate-intensity exercise have a healthier level of glucose metabolism in the brain — considered a reflection of how healthy and active the brain really is. In contrast, low-intensity physical activity, such as a slow walk, was not related to brain…
Patients with Alzheimer’s disease who experience delusions and hallucinations are five times more likely to be misdiagnosed than Alzheimer’s patients without psychosis, new research from St. Michael’s Hospital in Toronto, Canada, found. The study, “Determining the impact of…
AgeneBio has received a $750,000 grant from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of a novel GABAA discovery program targeting hippocampal overactivity in the brain, which is thought to contribute to neurodegeneration and cognitive decline in Alzheimer’s disease (AD) patients. AgeneBio’s pipeline of therapies is…
An enzyme called asparagine endopeptidase contributes to Parkinson’s as well as Alzheimer’s by slicing off fragments of proteins that end up being toxic, a study reports. Previous researched showed that the enzyme, also known as AEP, plays a role in Alzheimer’s. The new study indicates it plays a role in Parkinson’s,…
William Glass, who has seen the devastating toll that Alzheimer’s disease inflicts on families as a caregiver for his mother, is setting out on a 640-mile walk from Atlanta to Washington, D.C., to raise awareness of the disease and advocate for Congress to increase funding for research. The Chicago native…
Patients with dementia or other neurodegenerative diseases may die earlier if family members who act as caregivers have poor mental health, according to a study published recently in the Proceedings of the National Academy of Sciences (PNAS). While depression and anxiety among caregivers has been linked to a poorer…
Araclon Biotech is launching a Phase 2 clinical trial evaluating its active immunotherapy, or vaccine, ABvac40 for Alzheimer’s disease, after receiving approval from the Spanish Agency of Medicinal Products and Medical Devices. The multi-center trial will include 22 European clinical facilities (18 centers in Spain, two in France, one in Sweden…
Data from Phase 3 trials of tramiprosate (ALZ-801) suggest that the therapy might be modifying the disease course in patients with mild Alzheimer’s disease and two copies of the APOE4 gene, the drug’s developer, Alzheon, recently announced. With data in hand, the Framingham, Massachusetts, company plans to further clinical…
Various studies have contended that diets, supplements, exercise regimens, and games aimed at promoting cognitive function can help prevent Alzheimer’s disease or other dementias. But experts from a respected non-government-affiliated American scientific organization say there isn’t enough evidence supporting these approaches to mount a public-education campaign that promotes them. The judgment…
Get regular updates to your inbox.